Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To compare the proportion of patients demonstrating Major Molecular Response (MMR) at 12 months (48 weeks) in the bosutinib arm with that of the imatinib arm in newly diagnosed Philadelphia chromosome positive (Ph+) chronic phase (CP) chronic myelogenous leukemia (CML) patients harbouring b2a2 and/or b3a2 transcripts.
Critère d'inclusion
- Chronic Myeloid Leukemia (CML)